Zhejiang Tianyu Pharmaceutical's share price drop may be due to the broader market's 15% decline and the company's EPS loss. Despite the sell-off, long-term investors might see this as an opportunity given the 4% annual return over five years.

Investor worries over Zhejiang Tianyu Pharmaceutical's slowing revenue could explain its low P/S ratio. The company needs notable financial uplift to justify ratio increase. Its lackluster future prospects compared to industry may clarify its current P/S status.